Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome
NCT ID: NCT02050607
Last Updated: 2020-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2014-01-31
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our primary aim is to evaluate if FMT from lean healthy donors, in association to lifestyle changes, is able to reduce insulin-resistance more than lifestyle changes alone in patients with metabolic syndrome.
All the patients with metabolic syndrome will receive lifestyle counselling (1400 kilocalories diet and physical activity encouragement), than will be randomized to FMT from healthy lean donors by upper endoscopy (group A) or no treatment (group B)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Fecal Microbiota Transplantation in Slow Transit Constipation
NCT02301221
Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation
NCT02291354
Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment
NCT06368895
Efficacy and Safety of Fecal Microbiota Transplantation for Chronic Intestinal Pseudo-obstruction
NCT02731183
Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation
NCT02526849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Control group
No interventions assigned to this group
Fecal microbiota transplantation
Fecal microbiota transplantation from healthy lean donors
fecal microbiota transplantation from healthy lean donors
fecal microbiota transplantation from healthy lean donors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fecal microbiota transplantation from healthy lean donors
fecal microbiota transplantation from healthy lean donors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI\>30 and \>35 kg/m2
* Diagnosis of Metabolic Syndrome according to National Cholesterol Education Program's Adult Treatment Panel III criteria
* No ongoing therapy for diabetes, hyperlipidemia or arterial hypertension
* Signature of written informed consent
Exclusion Criteria
* Increase in triglycerides levels, (≥ 300 mg/dl), LDL levels (≥ 190 mg/dl, or modification of body weight (±5%) during the last 3 months
* Relevant cardiovascular diseases or kidney diseases
* Relevant gastrointestinal diseases (such as inflammatory bowel disease or celiac disease)
* Former gastrointestinal surgery
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catholic University of the Sacred Heart
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giovanni Cammarota
Prof
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic University of Sacred Heart - "A. Gemelli" University Hospital
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMTandMETs-002
Identifier Type: OTHER
Identifier Source: secondary_id
FMTandMETs-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.